As we keep emphasizing, the AI revolution is nowhere near finished. If anything, AI solutions are now being integrated into new sectors (pharmaceuticals, medical device companies).
As we noted last week, Nvidia (NVDA) is partnering with drug giant Novo Nordisk (NVO) for new drug discovery programs. As FirstWord Pharma noted:
Together, the pair (NVDA and NV) will plumb Novo Nordisk’s library of scientific literature to inform biomedical large language models intended to find correlations between genes, proteins and diseases…
On the discovery front, Novo Nordisk will use a range of NVIDIA offerings to build single-cell algorithms capable of predicting cellular responses to drug candidates and structures, as well as models that can build molecules with drug-like properties.
Source: FirstWord Pharma
NVO is not the only pharmaceutical company NVDA is teaming up with. Late last week it was announced that healthcare giant IQVIA (formerly Quintiles and IMS health, stock symbol IQV) will be using NVDA to power AI-based lab assistants to help its scientists in the development of clinical trials.
IQVIA said its AI agents can support a range of applications, including identifying drug targets, reviewing clinical and scientific literature, analysing clinical data, assessing market opportunities and engaging with healthcare providers.
Source: FirstWord Pharma
As I noted last week, AI has tremendous potential to expedite this process. LLMs can run countless simulations of a specific drug’s development, identifying risks or previously unknown potential where humans cannot.
Both NVO and IQV’s charts are showing promise.
NVO has just broken out of an eight-month downtrend. It is now challenging overhead resistance at $80. A break above that level would open the door to a move to $105.
By way of contrast, IQV shares remain in a downtrend channel (blue lines), but their recent breakout above resistance at $155 opens the door to a run to the top of the channel.
These are yet more illustrations of our dominant theme: that it is NOT too late to find opportunities to profit from AI-related technological breakthroughs. We are still very much in the adoption phase of AI for many sectors of the economy.
This is great news for investors because it means there’s still a lot of money to be made from this trend. So, if you missed out on the first wave of the AI revolution (the introduction of LLMs) don’t worry, there’s still PLENTY of opportunities to leverage the impact of AI towards profitable investing.
On that note, we just published a new special investment report The AI Plays Your Broker Doesn’t Know About that details three unique investments designed to profit from the revolution in physical AI. Best of all, Wall Street has little to no idea these companies even exist, let alone their potential.
We are making just 99 copies available to the general public. To pick up yours…
Best Regards
Graham Summers, MBA
Chief Market Strategist
Phoenix Capital Research
